Logo

Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Share this

Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Shots:

  • The first patient has been dosed in the P-II AAVIATE trial to assess the suprachoroidal delivery of RGX-314 (2.5x1011 GC/eye & 5x1011 GC/eye) vs ranibizumab (0.5mg- monthly- IVT) using the SCS Microinjector in ~40 patients in a ratio (3:1) with wet AMD
  • The 1EPs of the study is mean change in vision in patients dosed with RGX-314- as measured by BCVA @40wks.- other endpoints include mean change in CRT and number of anti-VEGF IVT received following administration of RGX-314
  • The company expects to report interim data of the first cohort of the trial by the end of 2020. RGX-314 is consists of the NAV AAV8 vector- being developed as a potential one-time treatment for wet AMD- diabetic retinopathy- and other chronic retinal conditions and has shown a positive effect in patients with wet AMD when delivered subretinally in the ongoing P-I/IIa study

­ Ref: Regenxbio | Image: Regenxbio

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions